NEW YORK (GenomeWeb) – NanoString Technologies has signed a deal with Medivation and Astellas Pharma to develop a companion diagnostic for the biopharmaceutical companies' investigational breast cancer drug enzalutamide.

Enzalutamide is an antiandrogen developed by Medivation and Astellas and approved for the treatment of metastatic castration-resistant prostate cancer in 2012 under the name Xtandi. The drug has also shown promise in triple-negative breast cancer patients. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.